OncoLink Cancer Treatment and Resources

Morbidity following Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection for Patients with Breast Carcinoma

Peter Schrenk, Roman Rieger, Andreas Shamiyeh, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Reviewers: Li Liu, MD
Source: Cancer, Volume 88:608-614, (February) 2000

Précis: Sentinel lymph nodes biopsy is associated with negligible morbidity

Introduction

The histologic status of axillary lymph nodes, one of the most important prognostic indicators in patients with breast cancer, directly affects clinical management. However, over 80% of women who undergo axillary dissection have at least one postoperative complication in the arm, and psychological distress is common (Canadian Journal Surgery 1993 Aug; 36(4): 315-20). A potential alternative to axillary lymphadenectomy is sentinel lymph node (SLN) biopsy. In this study, the researchers looked at the morbidity associated with SLN biopsy.

Method

In this study, the researchers prospectively compared morbidity rates for 35 women undergoing SLN biopsy and 35 women undergoing complete axillary lymph node dissection. All patients were free of lymph node metastases.

Results

  • Axillary lymph node dissection was associated with a significant increase in upper and forearm lymphedema, numbness, and motion restriction of the operated arm compared with the SLN biopsy.
  • Arm stiffness and strength did not differ between the two groups.
  • Neither surgical procedure significantly affected activities of daily living.

Discussion

In this study, sentinel lymph node biopsies were associated with considerably less postoperative morbidity than axillary lymph node dissection in women with breast cancer. Like other new medical techniques, there is a learning curve for surgeons. The procedure can be technically challenging and the success rate and morbidity varies among surgeons and according to the patient characteristics.

OncoLink I wish u knew...

Dr. O'Dwyer discusses pancreatic cancer, family history, screening and future research. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS